{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:31:09Z","timestamp":1789471869562,"version":"build-2803163510"},"reference-count":344,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1096,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1124\/pharmrev.120.000133","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T10:50:22Z","timestamp":1641898222000},"page":"207-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Therapeutics in the Pipeline Targeting \u03b1-Synuclein for Parkinson's Disease"],"prefix":"10.1016","volume":"74","author":[{"given":"Hilary","family":"Grosso Jasutkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Maral","family":"Mouradian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.120.000133_bib1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00775-019-01731-9","article-title":"Redox active metals in neurodegenerative diseases","volume":"24","author":"Acevedo","year":"2019","journal-title":"J Biol Inorg Chem"},{"key":"10.1124\/pharmrev.120.000133_bib2","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new glucocerebrosidase chaperone reduces \u03b1-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib3","doi-asserted-by":"crossref","first-page":"240ra273","DOI":"10.1126\/scitranslmed.3008659","article-title":"Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs","volume":"6","author":"Aflaki","year":"2014","journal-title":"Science Translational Medicine"},{"key":"10.1124\/pharmrev.120.000133_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1212\/01.wnl.0000271080.53272.c7","article-title":"alpha-Synuclein gene duplication is present in sporadic Parkinson disease","volume":"70","author":"Ahn","year":"2008","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000133_bib5","doi-asserted-by":"crossref","first-page":"102944","DOI":"10.1016\/j.ebiom.2020.102944","article-title":"Anti-\u03b1-synuclein ASO delivered to monoamine neurons prevents \u03b1-synuclein accumulation in a Parkinson\u2019s disease-like mouse model and in monkeys","volume":"59","author":"Alarc\u00f3n-Ar\u00eds","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1124\/pharmrev.120.000133_bib6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","article-title":"Selective \u03b1-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson\u2019s disease","volume":"26","author":"Alarc\u00f3n-Ar\u00eds","year":"2018","journal-title":"Mol Ther"},{"key":"10.1124\/pharmrev.120.000133_bib7","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/brain\/awv179","article-title":"Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations","volume":"138","author":"Alcalay","year":"2015","journal-title":"Brain"},{"key":"10.1124\/pharmrev.120.000133_bib8","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1093\/hmg\/ddp346","article-title":"LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model","volume":"18","author":"Alegre-Abarrategui","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1124\/pharmrev.120.000133_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fneur.2020.00437","article-title":"Exploring sphingolipid implications in neurodegeneration","volume":"11","author":"Alessenko","year":"2020","journal-title":"Front Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib10","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib11","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1096\/fj.03-0829fje","article-title":"Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson\u2019s disease","volume":"18","author":"Andringa","year":"2004","journal-title":"FASEB J"},{"key":"10.1124\/pharmrev.120.000133_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/mds.25421","article-title":"Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson\u2019s disease","volume":"28","author":"Appel-Cresswell","year":"2013","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib13","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1038\/s41467-018-05958-z","article-title":"LRRK2 kinase regulates \u03b1-synuclein propagation via RAB35 phosphorylation","volume":"9","author":"Bae","year":"2018","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000133_bib14","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib15","doi-asserted-by":"crossref","first-page":"eaav0820","DOI":"10.1126\/scitranslmed.aav0820","article-title":"LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits","volume":"12","author":"Baptista","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000133_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000133_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1471-4159.2006.04140.x","article-title":"Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders","volume":"100","author":"Battaglia","year":"2007","journal-title":"J Neurochem"},{"key":"10.1124\/pharmrev.120.000133_bib18","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","article-title":"The function of \u03b1-synuclein","volume":"79","author":"Bendor","year":"2013","journal-title":"Neuron"},{"key":"10.1124\/pharmrev.120.000133_bib19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense drugs make sense for neurological diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.120.000133_bib20","doi-asserted-by":"crossref","first-page":"33855","DOI":"10.1074\/jbc.274.48.33855","article-title":"Degradation of alpha-synuclein by proteasome","volume":"274","author":"Bennett","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib21","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1073\/pnas.0407146102","article-title":"Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein","volume":"102","author":"Bertoncini","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3233\/JPD-130252","article-title":"Can intrabodies serve as neuroprotective therapies for Parkinson\u2019s disease? Beginning thoughts","volume":"3","author":"Bhatt","year":"2013","journal-title":"J Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib23","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00401-019-01995-0","article-title":"LRRK2 modifies \u03b1-syn pathology and spread in mouse models and human neurons","volume":"137","author":"Bieri","year":"2019","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000133_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000318","article-title":"Identification of N-linked glycans as specific mediators of neuronal uptake of acetylated \u03b1-synuclein","volume":"17","author":"Birol","year":"2019","journal-title":"PLoS Biol"},{"key":"10.1124\/pharmrev.120.000133_bib25","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/mds.27659","article-title":"Parkinson\u2019s disease age at onset genome-wide association study: defining heritability, genetic loci, and \u03b1-synuclein mechanisms","volume":"34","author":"Blauwendraat","year":"2019","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"10.1124\/pharmrev.120.000133_bib26","first-page":"II3","article-title":"Pathoanatomy of Parkinson\u2019s disease","volume":"247","author":"Braak","year":"2000","journal-title":"J Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1124\/pharmrev.120.000133_bib28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00401-007-0193-x","article-title":"Parkinson\u2019s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons","volume":"113","author":"Braak","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000133_bib29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/JPD-171191","article-title":"c-Abl and Parkinson\u2019s disease: mechanisms and therapeutic potential","volume":"7","author":"Brahmachari","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib30","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"10.1124\/pharmrev.120.000133_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00018-012-1061-y","article-title":"The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK\/ERK pathway","volume":"70","author":"Bravo-San Pedro","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"10.1124\/pharmrev.120.000133_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbadis.2011.10.002","article-title":"\u03b1-Synuclein misfolding and Parkinson\u2019s disease","volume":"1822","author":"Breydo","year":"2012","journal-title":"Biochimica et Biophysica Acta (BBA) -. Molecular Basis of Disease"},{"key":"10.1124\/pharmrev.120.000133_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1021\/acs.bioconjchem.8b00799","article-title":"Endosomal escape and cytosolic penetration of macromolecules mediated by synthetic delivery agents","volume":"30","author":"Brock","year":"2019","journal-title":"Bioconjug Chem"},{"issue":"Pt B","key":"10.1124\/pharmrev.120.000133_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","article-title":"Therapeutic approaches to target alpha-synuclein pathology","volume":"298","author":"Brundin","year":"2017","journal-title":"Exp Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib35","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","article-title":"The risk of Parkinson\u2019s disease in type 1 Gaucher disease","volume":"33","author":"Bultron","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1124\/pharmrev.120.000133_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1126\/scitranslmed.aau6870","article-title":"A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson\u2019s disease","volume":"11","author":"Burbulla","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000133_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1101\/cshperspect.a024091","article-title":"Cell biology and pathophysiology of \u03b1-synuclein","volume":"8","author":"Burr\u00e9","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1124\/pharmrev.120.000133_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165964","article-title":"Bifunctional anti-non-amyloid component \u03b1-synuclein nanobodies are protective in situ","volume":"11","author":"Butler","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000133_bib40","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1523\/JNEUROSCI.22-20-08797.2002","article-title":"Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein","volume":"22","author":"Cabin","year":"2002","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib41","first-page":"4318416","article-title":"Genetic variants in SNCA and the risk of sporadic Parkinson\u2019s disease and clinical outcomes: a review","volume":"2017","author":"Camp\u00ealo","year":"2017","journal-title":"Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s13311-014-0310-1","article-title":"Commonalities and challenges in the development of clinical trial measures in neurology","volume":"12","author":"Cedarbaum","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1124\/pharmrev.120.000133_bib43","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809014","article-title":"USP14 inhibition corrects an in vivo model of impaired mitophagy","volume":"10","author":"Chakraborty","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1124\/pharmrev.120.000133_bib44","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/antiox9070597","article-title":"The role of oxidative stress in Parkinson\u2019s disease","volume":"9","author":"Chang","year":"2020","journal-title":"Antioxidants"},{"key":"10.1124\/pharmrev.120.000133_bib46","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"Alpha-synuclein locus duplication as a cause of familial Parkinson\u2019s disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000133_bib47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41531-018-0062-4","article-title":"Proteasome-targeted nanobodies alleviate pathology and functional decline in an \u03b1-synuclein-based Parkinson\u2019s disease model","volume":"4","author":"Chatterjee","year":"2018","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib48","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/hmg\/dds470","article-title":"MicroRNA-205 regulates the expression of Parkinson\u2019s disease-related leucine-rich repeat kinase 2 protein","volume":"22","author":"Cho","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1124\/pharmrev.120.000133_bib49","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neulet.2018.05.009","article-title":"MicroRNA-7 facilitates the degradation of alpha-synuclein and its aggregates by promoting autophagy","volume":"678","author":"Choi","year":"2018","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.120.000133_bib50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.nbd.2009.05.023","article-title":"Alterations in lysosomal and proteasomal markers in Parkinson\u2019s disease: relationship to alpha-synuclein inclusions","volume":"35","author":"Chu","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000133_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0197-0186(01)00062-6","article-title":"Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration","volume":"40","author":"Citron","year":"2002","journal-title":"Neurochem Int"},{"key":"10.1124\/pharmrev.120.000133_bib52","doi-asserted-by":"crossref","first-page":"P6.239","DOI":"10.1212\/WNL.86.16_supplement.P6.239","article-title":"SNCA targeted antisense oligonucleotides mediate progression of pathological deposition in alpha synuclein rodent transmission models of Parkinson\u2019s disease (P6.239)","volume":"86","author":"Cole","year":"2016","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000133_bib53","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1172\/jci.insight.135633","article-title":"\u03b1-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson\u2019s disease","volume":"6","author":"Cole","year":"2021","journal-title":"JCI Insight"},{"key":"10.1124\/pharmrev.120.000133_bib54","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4103\/1673-5374.235013","article-title":"Subcellular localization of alpha-synuclein aggregates and their interaction with membranes","volume":"13","author":"Miraglia","year":"2018","journal-title":"Neural Regen Res"},{"key":"10.1124\/pharmrev.120.000133_bib55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fnins.2016.00012","article-title":"Is alpha-synuclein loss-of-function a contributor to Parkinsonian pathology? Evidence from non-human primates","volume":"10","author":"Collier","year":"2016","journal-title":"Front Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/cts.12492","article-title":"Dopamine transporter neuroimaging as an enrichment biomarker in early Parkinson\u2019s disease clinical trials: a disease progression modeling analysis","volume":"11","author":"Conrado","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1124\/pharmrev.120.000133_bib57","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1073\/pnas.97.2.571","article-title":"Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson\u2019s disease: implications for pathogenesis and therapy","volume":"97","author":"Conway","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib58","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib59","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","article-title":"Direct observation of the interconversion of normal and toxic forms of \u03b1-synuclein","volume":"149","author":"Cremades","year":"2012","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000133_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009313","article-title":"Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of \u03b1-synucleinopathy","volume":"5","author":"Crews","year":"2010","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000133_bib61","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000133_bib62","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-3-319-49969-7_11","article-title":"Interaction of LRRK2 and \u03b1-synuclein in Parkinson\u2019s disease","volume":"14","author":"Daher","year":"2017","journal-title":"Adv Neurobiol"},{"key":"10.1124\/pharmrev.120.000133_bib63","doi-asserted-by":"crossref","first-page":"19433","DOI":"10.1074\/jbc.M115.660001","article-title":"Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates \u03b1-synuclein gene-induced neurodegeneration","volume":"290","author":"Daher","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib64","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.neulet.2005.01.034","article-title":"Alpha-synuclein binding to rab3a in multiple system atrophy","volume":"380","author":"Dalf\u00f3","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.120.000133_bib65","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","article-title":"Different species of alpha-synuclein oligomers induce calcium influx and seeding","volume":"27","author":"Danzer","year":"2007","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib66","first-page":"1419","article-title":"Trehalose neuroprotective effects on the substantia Nigra dopaminergic cells by activating autophagy and non-canonical Nrf2 pathways","volume":"18","author":"Darabi","year":"2019","journal-title":"Iran J Pharm Res"},{"key":"10.1124\/pharmrev.120.000133_bib67","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","article-title":"Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease","volume":"73","author":"Davis","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib68","doi-asserted-by":"crossref","first-page":"E1817","DOI":"10.1073\/pnas.1305623110","article-title":"TFEB-mediated autophagy rescues midbrain dopamine neurons from \u03b1-synuclein toxicity","volume":"110","author":"Decressac","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib69","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib70","doi-asserted-by":"crossref","first-page":"12535","DOI":"10.1523\/JNEUROSCI.1920-10.2010","article-title":"Pathogenic lysosomal depletion in Parkinson\u2019s disease","volume":"30","author":"Dehay","year":"2010","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib71","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nchembio.538","article-title":"Characterization of a selective inhibitor of the Parkinson\u2019s disease kinase LRRK2","volume":"7","author":"Deng","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1124\/pharmrev.120.000133_bib72","doi-asserted-by":"crossref","first-page":"13010","DOI":"10.1073\/pnas.0903691106","article-title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein","volume":"106","author":"Desplats","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib73","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00702-019-02138-1","article-title":"Conservative iron chelation for neurodegenerative diseases such as Parkinson\u2019s disease and amyotrophic lateral sclerosis","volume":"127","author":"Devos","year":"2020","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1124\/pharmrev.120.000133_bib74","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/ars.2013.5593","article-title":"Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease","volume":"21","author":"Devos","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"10.1124\/pharmrev.120.000133_bib75","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00702-010-0531-3","article-title":"Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson\u2019s disease after peripheral administration","volume":"118","author":"Dexter","year":"2011","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1124\/pharmrev.120.000133_bib76","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/JPD-130230","article-title":"The role of oxidative stress in Parkinson\u2019s disease","volume":"3","author":"Dias","year":"2013","journal-title":"J Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cbpa.2020.01.001","article-title":"Progress toward the development of the small molecule equivalent of small interfering RNA","volume":"56","author":"Disney","year":"2020","journal-title":"Curr Opin Chem Biol"},{"key":"10.1124\/pharmrev.120.000133_bib78","doi-asserted-by":"crossref","first-page":"12726","DOI":"10.1074\/jbc.M109.086827","article-title":"Post-transcriptional regulation of \u03b1-synuclein expression by mir-7 and mir-153","volume":"285","author":"Doxakis","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib79","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/antiox10030453","article-title":"Antioxidant therapeutics in Parkinson\u2019s disease: current challenges and opportunities","volume":"10","author":"Duarte-Jurado","year":"2021","journal-title":"Antioxidants"},{"key":"10.1124\/pharmrev.120.000133_bib80","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1523\/JNEUROSCI.1560-11.2011","article-title":"Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of \u03b1-synuclein","volume":"31","author":"Ebrahimi-Fakhari","year":"2011","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib81","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1096\/fj.03-0098fje","article-title":"Alpha-synuclein implicated in Parkinson\u2019s disease is present in extracellular biological fluids, including human plasma","volume":"17","author":"El-Agnaf","year":"2003","journal-title":"FASEB J"},{"key":"10.1124\/pharmrev.120.000133_bib82","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neuroscience.2021.01.017","article-title":"The localization of alpha-synuclein in the endocytic pathway","volume":"457","author":"Fakhree","year":"2021","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.120.000133_bib83","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.molcel.2018.11.028","article-title":"Lipidomic analysis of \u03b1-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment","volume":"73","author":"Fanning","year":"2019","journal-title":"Mol Cell"},{"key":"10.1124\/pharmrev.120.000133_bib84","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ana.10846","article-title":"Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications","volume":"55","author":"Farrer","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib85","doi-asserted-by":"crossref","first-page":"15345","DOI":"10.1074\/jbc.M111.318949","article-title":"\u03b1-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer","volume":"287","author":"Fauvet","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib86","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.115.227587","article-title":"MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition","volume":"355","author":"Fell","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.120.000133_bib87","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fnins.2016.00099","article-title":"Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy","volume":"10","author":"Fellner","year":"2016","journal-title":"Front Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib88","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbr.2015.05.057","article-title":"Chronic MPTP treatment produces hyperactivity in male mice which is not alleviated by concurrent trehalose treatment","volume":"292","author":"Ferguson","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.1124\/pharmrev.120.000133_bib89","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-017-0456-2","article-title":"The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson\u2019s disease","volume":"5","author":"Finkelstein","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1124\/pharmrev.120.000133_bib90","series-title":"Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging","first-page":"117","article-title":"Macroautophagy of Aggregation-Prone Proteins in Neurodegenerative Disease","author":"Fox","year":"2015"},{"key":"10.1124\/pharmrev.120.000133_bib91","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1096\/fj.07-9348com","article-title":"Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain","volume":"22","author":"Fuchs","year":"2008","journal-title":"FASEB J"},{"key":"10.1124\/pharmrev.120.000133_bib92","doi-asserted-by":"crossref","first-page":"273ra15","DOI":"10.1126\/scitranslmed.aaa3634","article-title":"Effect of selective LRRK2 kinase inhibition on nonhuman primate lung","volume":"7","author":"Fuji","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000133_bib93","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"alpha-Synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat Cell Biol"},{"key":"10.1124\/pharmrev.120.000133_bib94","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib95","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1212\/01.wnl.0000304039.11891.29","article-title":"Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset","volume":"70","author":"Gan-Or","year":"2008","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000133_bib96","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41467-021-21022-9","article-title":"Blood-brain barrier opening with focused ultrasound in Parkinson\u2019s disease dementia","volume":"12","author":"Gasca-Salas","year":"2021","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000133_bib97","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/380252a0","article-title":"Functional recovery in parkinsonian monkeys treated with GDNF","volume":"380","author":"Gash","year":"1996","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000133_bib98","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1474-4422(17)30045-5","article-title":"Solving the conundrum of insoluble protein aggregates","volume":"16","author":"George","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib99","doi-asserted-by":"crossref","first-page":"368ra174","DOI":"10.1126\/scitranslmed.aag2210","article-title":"Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson\u2019s disease","volume":"8","author":"Ghosh","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000133_bib100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijbiomac.2016.10.021","article-title":"\u03b1-synuclein aggregation and its modulation","volume":"100","author":"Ghosh","year":"2017","journal-title":"Int J Biol Macromol"},{"key":"10.1124\/pharmrev.120.000133_bib101","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1074\/jbc.M008919200","article-title":"A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly","volume":"276","author":"Giasson","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib102","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"issue":"s1","key":"10.1124\/pharmrev.120.000133_bib103","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3233\/JPD-179005","article-title":"The synucleinopathies: twenty years on","volume":"7","author":"Goedert","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib104","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","article-title":"100 years of Lewy pathology","volume":"9","author":"Goedert","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib105","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2010.115","article-title":"In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration","volume":"18","author":"Gorbatyuk","year":"2010","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"10.1124\/pharmrev.120.000133_bib106","doi-asserted-by":"crossref","first-page":"8043","DOI":"10.3390\/ijms21218043","article-title":"Multiplicity of \u03b1-synuclein aggregated species and their possible roles in disease","volume":"21","author":"Gracia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1124\/pharmrev.120.000133_bib107","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12883-015-0331-3","article-title":"Ceruloplasmin activity and iron chelation treatment of patients with Parkinson\u2019s disease","volume":"15","author":"Grolez","year":"2015","journal-title":"BMC Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib108","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/mds.108","article-title":"\u03b22-adrenoceptor agonists and antagonists and risk of Parkinson\u2019s disease","volume":"33","author":"Gronich","year":"2018","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib109","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.pharmthera.2011.12.003","article-title":"Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications","volume":"133","author":"Grosso","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pharmrev.120.000133_bib110","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1096\/fj.14-251413","article-title":"Transglutaminase 2 exacerbates \u03b1-synuclein toxicity in mice and yeast","volume":"28","author":"Grosso","year":"2014","journal-title":"FASEB J"},{"key":"10.1124\/pharmrev.120.000133_bib111","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","article-title":"Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry","volume":"10","author":"Hamilton","year":"2000","journal-title":"Brain Pathol"},{"key":"10.1124\/pharmrev.120.000133_bib112","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1021\/acsmedchemlett.5b00064","article-title":"Discovery of a pyrrolopyrimidine (JH-II-127), a highly potent, selective, and brain penetrant LRRK2 inhibitor","volume":"6","author":"Hatcher","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/pharmrev.120.000133_bib113","first-page":"2","article-title":"Targeting neurons in the gastrointestinal tract to treat Parkinson\u2019s disease","volume":"1","author":"Hauser","year":"2019","journal-title":"Clin Park Relat Disord"},{"key":"10.1124\/pharmrev.120.000133_bib114","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbrc.2006.01.057","article-title":"Down-regulation of \u03b1-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson\u2019s disease rat model","volume":"341","author":"Hayashita-Kinoh","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pharmrev.120.000133_bib115","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1007\/s12035-015-9173-7","article-title":"Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV \u03b1-synuclein rat model of Parkinson\u2019s disease","volume":"53","author":"He","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.1124\/pharmrev.120.000133_bib116","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib117","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson\u2019s disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1124\/pharmrev.120.000133_bib118","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4172\/2155-9899.1000259","article-title":"Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in \u03b1-synucleinopathy","volume":"5","author":"Hebron","year":"2014","journal-title":"J Clin Cell Immunol"},{"key":"10.1124\/pharmrev.120.000133_bib119","article-title":"A randomized single and multiple ascending dose study in healthy volunteers of LTI\u2010291, a centrally penetrant glucocerebrosidase activator","author":"Heijer","year":"2021","journal-title":"British Journal of Clinical Pharmacology."},{"key":"10.1124\/pharmrev.120.000133_bib120","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/mds.27724","article-title":"Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson\u2019s disease","volume":"34","author":"Heiss","year":"2019","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib121","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omtn.2017.08.013","article-title":"Polyethylenimine nanoparticle-mediated siRNA delivery to reduce \u03b1-synuclein expression in a model of Parkinson\u2019s disease","volume":"9","author":"Helmschrodt","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/pharmrev.120.000133_bib122","doi-asserted-by":"crossref","first-page":"104712","DOI":"10.1016\/j.nbd.2019.104712","article-title":"Characterization of novel conformation-selective \u03b1-synuclein antibodies as potential immunotherapeutic agents for Parkinson\u2019s disease","volume":"136","author":"Henderson","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000133_bib123","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mds.27562","article-title":"Anle138b modulates \u03b1-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy","volume":"34","author":"Heras-Garvin","year":"2019","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib124","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00401-012-1013-5","article-title":"The genetics and neuropathology of Parkinson\u2019s disease","volume":"124","author":"Houlden","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000133_bib125","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/jpet.118.255695","article-title":"Beneficial effects of trehalose on striatal dopaminergic deficits in rodent and primate models of synucleinopathy in Parkinson\u2019s disease","volume":"369","author":"Howson","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.120.000133_bib126","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3390\/genes12040505","article-title":"LRRK2 at the crossroad of aging and Parkinson\u2019s disease","volume":"12","author":"Hur","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1124\/pharmrev.120.000133_bib127","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbamcr.2012.11.018","article-title":"Maturation of autophagosomes and endosomes: a key role for Rab7","volume":"1833","author":"Hyttinen","year":"2013","journal-title":"Biochimica et Biophysica Acta (BBA) -. Molecular Cell Research"},{"key":"10.1124\/pharmrev.120.000133_bib128","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(04)17104-3","article-title":"Causal relation between alpha-synuclein gene duplication and familial Parkinson\u2019s disease","volume":"364","author":"Ib\u00e1\u00f1ez","year":"2004","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000133_bib129","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archneurol.2008.555","article-title":"Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms","volume":"66","author":"Ib\u00e1\u00f1ez","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib130","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archneur.65.4.514","article-title":"Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia","volume":"65","author":"Ikeuchi","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib131","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib132","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0896-6273(95)90302-X","article-title":"The precursor protein of non-A beta component of Alzheimer\u2019s disease amyloid is a presynaptic protein of the central nervous system","volume":"14","author":"Iwai","year":"1995","journal-title":"Neuron"},{"key":"10.1124\/pharmrev.120.000133_bib133","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.2174\/1568026615666150610125856","article-title":"Age-related neurodegeneration prevention through mTOR inhibition: potential mechanisms and remaining questions","volume":"15","author":"Jahrling","year":"2015","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/pharmrev.120.000133_bib134","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib135","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1523\/JNEUROSCI.6119-09.2010","article-title":"Methylation regulates alpha-synuclein expression and is decreased in Parkinson\u2019s disease patients\u2019 brains","volume":"30","author":"Jowaed","year":"2010","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib136","first-page":"S117","article-title":"Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a GBA mutation","volume":"126","author":"Judith Peterschmitt","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1124\/pharmrev.120.000133_bib137","doi-asserted-by":"crossref","first-page":"13052","DOI":"10.1073\/pnas.0906277106","article-title":"Repression of alpha-synuclein expression and toxicity by microRNA-7","volume":"106","author":"Junn","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib138","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0304-3940(02)00016-2","article-title":"Human \u03b1-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine","volume":"320","author":"Junn","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.120.000133_bib139","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.4161\/cc.9.9.11296","article-title":"MicroRNAs in neurodegenerative disorders","volume":"9","author":"Junn","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1124\/pharmrev.120.000133_bib140","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pharmthera.2011.10.002","article-title":"MicroRNAs in neurodegenerative diseases and their therapeutic potential","volume":"133","author":"Junn","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pharmrev.120.000133_bib141","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1073\/pnas.0438021100","article-title":"Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"100","author":"Junn","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib142","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.febslet.2014.12.014","article-title":"Inhibition of miR-34b and miR-34c enhances \u03b1-synuclein expression in Parkinson\u2019s disease","volume":"589","author":"Kabaria","year":"2015","journal-title":"FEBS Lett"},{"key":"10.1124\/pharmrev.120.000133_bib143","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.1523\/JNEUROSCI.20-17-06365.2000","article-title":"Subcellular localization of wild-type and Parkinson\u2019s disease-associated mutant alpha -synuclein in human and transgenic mouse brain","volume":"20","author":"Kahle","year":"2000","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib144","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000133_bib145","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1126\/science.aat8407","article-title":"Poly(ADP-ribose) drives pathologic \u03b1-synuclein neurodegeneration in Parkinson\u2019s disease","volume":"362","author":"Kam","year":"2018","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000133_bib146","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol Ther"},{"key":"10.1124\/pharmrev.120.000133_bib147","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/mds.27804","article-title":"Blood-brain barrier opening with focused ultrasound in experimental models of Parkinson\u2019s disease","volume":"34","author":"Karakatsani","year":"2019","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib148","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1038\/emboj.2009.257","article-title":"Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson\u2019s disease models","volume":"28","author":"Karpinar","year":"2009","journal-title":"EMBO J"},{"key":"10.1124\/pharmrev.120.000133_bib149","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41374-019-0195-z","article-title":"Transmission of \u03b1-synuclein seeds in neurodegenerative disease: recent developments","volume":"99","author":"Karpowicz","year":"2019","journal-title":"Lab Invest"},{"key":"10.1124\/pharmrev.120.000133_bib150","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/srep04874","article-title":"The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson\u2019s disease","volume":"4","author":"Karuppagounder","year":"2014","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.120.000133_bib151","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/mds.25499","article-title":"The many faces of alpha-synuclein mutations","volume":"28","author":"Kasten","year":"2013","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib152","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainres.2014.01.010","article-title":"Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects","volume":"1550","author":"Khodr","year":"2014","journal-title":"Brain Res"},{"key":"10.1124\/pharmrev.120.000133_bib153","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.brainres.2011.04.036","article-title":"An \u03b1-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson\u2019s disease, but displays toxicity in dopamine neurons","volume":"1395","author":"Khodr","year":"2011","journal-title":"Brain Res"},{"key":"10.1124\/pharmrev.120.000133_bib154","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00401-013-1096-7","article-title":"\u03b1-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson\u2019s disease and multiple system atrophy?","volume":"125","author":"Kiely","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000133_bib155","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron"},{"key":"10.1124\/pharmrev.120.000133_bib156","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1073\/pnas.1700465115","article-title":"GBA1 deficiency negatively affects physiological \u03b1-synuclein tetramers and related multimers","volume":"115","author":"Kim","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib157","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.bbadis.2017.03.017","article-title":"Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: relevance to Alzheimer\u2019s disease","volume":"1863","author":"Kiprowska","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1124\/pharmrev.120.000133_bib158","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000133_bib159","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.jmb.2014.04.015","article-title":"A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies","volume":"426","author":"Krishnan","year":"2014","journal-title":"J Mol Biol"},{"key":"10.1124\/pharmrev.120.000133_bib160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease","volume":"18","author":"Kr\u00fcger","year":"1998","journal-title":"Nat Genet"},{"key":"10.1124\/pharmrev.120.000133_bib161","first-page":"1","article-title":"Translational inhibition of \u03b1-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice","volume":"8","author":"Kuo","year":"2019","journal-title":"Am J Neurodegener Dis"},{"key":"10.1124\/pharmrev.120.000133_bib162","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s13311-020-00853-2","article-title":"Immunotherapies for aging-related neurodegenerative diseases-emerging perspectives and new targets","volume":"17","author":"Kwon","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1124\/pharmrev.120.000133_bib163","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.106.112102","article-title":"The experimental Alzheimer\u2019s disease drug posiphen [(+)-phenserine] lowers amyloid-\u03b2 peptide levels in cell culture and mice","volume":"320","author":"Lahiri","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.120.000133_bib164","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature09299","article-title":"Enhancement of proteasome activity by a small-molecule inhibitor of USP14","volume":"467","author":"Lee","year":"2010","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000133_bib166","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1523\/JNEUROSCI.6513-10.2011","article-title":"Enhanced phosphatase activity attenuates \u03b1-synucleinopathy in a mouse model","volume":"31","author":"Lee","year":"2011","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib167","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13311-012-0165-2","article-title":"Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson\u2019s disease","volume":"10","author":"Lee","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1124\/pharmrev.120.000133_bib168","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","article-title":"The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson\u2019s disease mouse model","volume":"27","author":"Lee","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1124\/pharmrev.120.000133_bib169","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40035-020-00217-y","article-title":"Targeting \u03b1-synuclein by PD03 AFFITOPE\u00ae and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance","volume":"9","author":"Lemos","year":"2020","journal-title":"Transl Neurodegener"},{"key":"10.1124\/pharmrev.120.000133_bib170","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.23894","article-title":"G51D \u03b1-synuclein mutation causes a novel parkinsonian-pyramidal syndrome","volume":"73","author":"Lesage","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib171","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.trci.2016.06.004","article-title":"NPT088 reduces both amyloid-\u03b2 and tau pathologies in transgenic mice","volume":"2","author":"Levenson","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1124\/pharmrev.120.000133_bib172","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00401-014-1265-3","article-title":"The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset","volume":"127","author":"Levin","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000133_bib173","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1326-3-19","article-title":"In vivo silencing of alpha-synuclein using naked siRNA","volume":"3","author":"Lewis","year":"2008","journal-title":"Mol Neurodegener"},{"key":"10.1124\/pharmrev.120.000133_bib174","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/mds.27722","article-title":"Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson\u2019s disease","volume":"34","author":"LeWitt","year":"2019","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib175","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000133_bib176","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.1073\/pnas.1605245113","article-title":"Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain","volume":"113","author":"Li","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib177","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2014.05.009","article-title":"Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] \u03b1-synuclein mice","volume":"69","author":"Lindstr\u00f6m","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000133_bib178","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0002-9440(10)65722-7","article-title":"Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer\u2019s disease patients with mutations in presenilin and amyloid precursor protein genes","volume":"153","author":"Lippa","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1124\/pharmrev.120.000133_bib179","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11011-020-00630-2","article-title":"Crossing the blood-brain barrier with AAV vectors","volume":"36","author":"Liu","year":"2021","journal-title":"Metab Brain Dis"},{"key":"10.1124\/pharmrev.120.000133_bib180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083914","article-title":"Ubiquitination increases parkin activity to promote autophagic \u03b1-synuclein clearance","volume":"8","author":"Lonskaya","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000133_bib181","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000133_bib182","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1073\/pnas.1200575109","article-title":"Impaired neurotransmission caused by overexpression of \u03b1-synuclein in nigral dopamine neurons","volume":"109","author":"Lundblad","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib183","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/jnnp-2012-302589","article-title":"Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-\u03b2 peptide and \u03c4 levels: target engagement, tolerability and pharmacokinetics in humans","volume":"83","author":"Maccecchini","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/pharmrev.120.000133_bib184","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1073\/pnas.1913904117","article-title":"The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration","volume":"117","author":"Mahul-Mellier","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib185","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1523\/JNEUROSCI.3944-09.2010","article-title":"Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson\u2019s disease","volume":"30","author":"Malagelada","year":"2010","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib186","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2015","journal-title":"Mol Neurodegener"},{"key":"10.1124\/pharmrev.120.000133_bib187","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson\u2019s disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000133_bib188","doi-asserted-by":"crossref","first-page":"aah3374","DOI":"10.1126\/science.aah3374","article-title":"Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000133_bib189","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acn3.644","article-title":"The Parkinson\u2019s progression markers initiative (PPMI) - establishing a PD biomarker cohort","volume":"5","author":"Marek","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00401-008-0372-4","article-title":"Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson\u2019s disease. Variability in familial Parkinson\u2019s disease","volume":"116","author":"Markopoulou","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000133_bib191","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","article-title":"Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease","volume":"7","author":"Martin-Bastida","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.120.000133_bib192","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of \u03b1-synuclein immunization in a mouse model of Parkinson\u2019s disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"10.1124\/pharmrev.120.000133_bib193","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000133_bib194","doi-asserted-by":"crossref","first-page":"a008870","DOI":"10.1101\/cshperspect.a008870","article-title":"Clinical approach to Parkinson\u2019s disease: features, diagnosis, and principles of management","volume":"2","author":"Massano","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1124\/pharmrev.120.000133_bib195","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/brain\/awt037","article-title":"Prion-like spreading of pathological \u03b1-synuclein in brain","volume":"136","author":"Masuda-Suzukake","year":"2013","journal-title":"Brain"},{"key":"10.1124\/pharmrev.120.000133_bib196","doi-asserted-by":"crossref","unstructured":"Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou Y-S, Saiki S, Kawajiri S, Sato F, Kimura M, Komatsu M, Hattori N and Tanaka K (2010) PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. 189:211\u2013221.","DOI":"10.1083\/jcb.200910140"},{"key":"10.1124\/pharmrev.120.000133_bib197","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.1520335113","article-title":"\u03b1-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models","volume":"113","author":"Mazzulli","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib198","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of \u03b2-glucocerebrosidase reduces pathological \u03b1-synuclein and restores lysosomal function in Parkinson\u2019s patient midbrain neurons","volume":"36","author":"Mazzulli","year":"2016","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib199","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012122","article-title":"Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra","volume":"5","author":"McCormack","year":"2010","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000133_bib200","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000133_bib201","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/mds.28218","article-title":"A phase 1 randomized trial of specific active \u03b1-synuclein immunotherapies PD01A and PD03A in multiple system atrophy","volume":"35","author":"Meissner","year":"2020","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib202","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nm1752","article-title":"Dopamine neurons implanted into people with Parkinson\u2019s disease survive without pathology for 14 years","volume":"14","author":"Mendez","year":"2008","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000133_bib203","doi-asserted-by":"crossref","first-page":"104619","DOI":"10.1016\/j.nbd.2019.104619","article-title":"Optimizing intracellular antibodies (intrabodies\/nanobodies) to treat neurodegenerative disorders","volume":"134","author":"Messer","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000133_bib204","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1039\/D0CS00560F","article-title":"Small molecule recognition of disease-relevant RNA structures","volume":"49","author":"Meyer","year":"2020","journal-title":"Chem Soc Rev"},{"key":"10.1124\/pharmrev.120.000133_bib205","doi-asserted-by":"crossref","first-page":"228","DOI":"10.14283\/jpad.2019.37","article-title":"Randomized, placebo controlled trial of NPT088, a phage-derived, amyloid-targeted treatment for Alzheimer\u2019s disease","volume":"6","author":"Michelson","year":"2019","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1124\/pharmrev.120.000133_bib206","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice","volume":"80","author":"Migdalska-Richards","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib207","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/syn.21967","article-title":"Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate","volume":"71","author":"Migdalska-Richards","year":"2017","journal-title":"Synapse"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.120.000133_bib208","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jnc.13385","article-title":"The relationship between glucocerebrosidase mutations and Parkinson disease","volume":"139","author":"Migdalska-Richards","year":"2016","journal-title":"J Neurochem"},{"key":"10.1124\/pharmrev.120.000133_bib209","first-page":"142372","article-title":"The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson\u2019s alpha synuclein expression","volume":"2012","author":"Mikkilineni","year":"2012","journal-title":"Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib210","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"\u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000133_bib211","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/j.1471-4159.2008.05332.x","article-title":"Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells","volume":"105","author":"Molina-Holgado","year":"2008","journal-title":"J Neurochem"},{"key":"10.1124\/pharmrev.120.000133_bib212","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13024-017-0154-3","article-title":"Therapeutic potential of autophagy-enhancing agents in Parkinson\u2019s disease","volume":"12","author":"Moors","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.1124\/pharmrev.120.000133_bib213","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nbd.2011.12.046","article-title":"MicroRNAs in Parkinson\u2019s disease","volume":"46","author":"Mouradian","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000133_bib214","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib215","first-page":"CD012990","article-title":"GLP-1 receptor agonists for Parkinson\u2019s disease","volume":"7","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.120.000133_bib216","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat Genet"},{"key":"10.1124\/pharmrev.120.000133_bib217","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/19768354.2021.1883735","article-title":"Analysis of \u03b1-synuclein levels related to LRRK2 kinase activity: from substantia nigra to urine of patients with Parkinson\u2019s disease","volume":"25","author":"Nam","year":"2021","journal-title":"Anim Cells Syst (Seoul)"},{"key":"10.1124\/pharmrev.120.000133_bib218","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1083\/jcb.200809125","article-title":"Parkin is recruited selectively to impaired mitochondria and promotes their autophagy","volume":"183","author":"Narendra","year":"2008","journal-title":"J Cell Biol"},{"key":"10.1124\/pharmrev.120.000133_bib219","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/jnc.14222","article-title":"DJ-1 deficiency impairs autophagy and reduces alpha-synuclein phagocytosis by microglia","volume":"143","author":"Nash","year":"2017","journal-title":"J Neurochem"},{"key":"10.1124\/pharmrev.120.000133_bib220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","article-title":"Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis","volume":"65","author":"Nemani","year":"2010","journal-title":"Neuron"},{"key":"10.1124\/pharmrev.120.000133_bib221","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"10.1124\/pharmrev.120.000133_bib222","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13195-020-00727-x","article-title":"Novel antibodies detect additional \u03b1-synuclein pathology in synucleinopathies: potential development for immunotherapy","volume":"12","author":"Nimmo","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1124\/pharmrev.120.000133_bib223","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.20753","article-title":"Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson\u2019s disease","volume":"59","author":"Nishioka","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib224","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/mds.22682","article-title":"Expanding the clinical phenotype of SNCA duplication carriers","volume":"24","author":"Nishioka","year":"2009","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s10020-021-00279-2","article-title":"Novel targeted therapies for Parkinson\u2019s disease","volume":"27","author":"Ntetsika","year":"2021","journal-title":"Mol Med"},{"key":"10.1124\/pharmrev.120.000133_bib226","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ana.25920","article-title":"A stearoyl-coenzyme A desaturase inhibitor prevents multiple Parkinson disease phenotypes in \u03b1-synuclein mice","volume":"89","author":"Nuber","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib227","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1212\/01.wnl.0000299387.59159.db","article-title":"Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia","volume":"70","author":"Obi","year":"2008","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000133_bib228","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/oxfordjournals.jbchem.a124899","article-title":"Ribozymes: from mechanistic studies to applications in vivo","volume":"118","author":"Ohkawa","year":"1995","journal-title":"J Biochem"},{"key":"10.1124\/pharmrev.120.000133_bib229","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1074\/jbc.275.1.390","article-title":"Constitutive phosphorylation of the Parkinson\u2019s disease associated alpha-synuclein","volume":"275","author":"Okochi","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib230","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JPD-160779","article-title":"Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade?","volume":"6","author":"Oueslati","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib231","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMc055509","article-title":"LRRK2 G2019S as a cause of Parkinson\u2019s disease in Ashkenazi Jews","volume":"354","author":"Ozelius","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000133_bib232","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib233","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.470","article-title":"Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson\u2019s disease","volume":"7","author":"Pagan","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/pharmrev.120.000133_bib234","doi-asserted-by":"crossref","first-page":"16895","DOI":"10.1074\/jbc.M800747200","article-title":"Phosphorylation at Ser-129 but not the phosphomimics S129E\/D inhibits the fibrillation of \u03b1-synuclein","volume":"283","author":"Paleologou","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib235","doi-asserted-by":"crossref","first-page":"16895","DOI":"10.1074\/jbc.M800747200","article-title":"Phosphorylation at Ser-129 but not the phosphomimics S129E\/D inhibits the fibrillation of alpha-synuclein","volume":"283","author":"Paleologou","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib236","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/acn3.337","article-title":"Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies","volume":"3","author":"Park","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib237","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00401-008-0346-6","article-title":"Applicability of current staging\/categorization of alpha-synuclein pathology and their clinical relevance","volume":"115","author":"Parkkinen","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000133_bib238","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson\u2019s disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib239","doi-asserted-by":"crossref","first-page":"2180.e1","DOI":"10.1016\/j.neurobiolaging.2014.03.024","article-title":"Novel \u03b1-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson\u2019s disease-type pathology","volume":"35","author":"Pasanen","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.1124\/pharmrev.120.000133_bib240","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1530\/JME-10-0125","article-title":"GDNF and protection of adult central catecholaminergic neurons","volume":"46","author":"Pascual","year":"2011","journal-title":"J Mol Endocrinol"},{"key":"10.1124\/pharmrev.120.000133_bib241","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1021\/jm300063b","article-title":"Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase","volume":"55","author":"Patnaik","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.120.000133_bib242","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jmb.2004.02.014","article-title":"Structural determinants of PLD2 inhibition by alpha-synuclein","volume":"337","author":"Payton","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1124\/pharmrev.120.000133_bib243","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0034-1381737","article-title":"Multiple system atrophy","volume":"34","author":"Peeraully","year":"2014","journal-title":"Semin Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib244","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41582-020-0333-7","article-title":"Protein transmission in neurodegenerative disease","volume":"16","author":"Peng","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib245","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fphar.2020.00077","article-title":"Sphingosine-1-phosphate receptors modulators decrease signs of neuroinflammation and prevent Parkinson\u2019s disease symptoms in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model","volume":"11","author":"P\u00e9pin","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1124\/pharmrev.120.000133_bib246","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1021\/acschembio.8b00466","article-title":"Multistep inhibition of \u03b1-synuclein aggregation and toxicity in vitro and in vivo by trodusquemine","volume":"13","author":"Perni","year":"2018","journal-title":"ACS Chem Biol"},{"key":"10.1124\/pharmrev.120.000133_bib247","doi-asserted-by":"crossref","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","article-title":"A natural product inhibits the initiation of \u03b1-synuclein aggregation and suppresses its toxicity","volume":"114","author":"Perni","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib248","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000133_bib249","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mds.24996","article-title":"Identifying prodromal Parkinson\u2019s disease: pre-motor disorders in Parkinson\u2019s disease","volume":"27","author":"Postuma","year":"2012","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib250","doi-asserted-by":"crossref","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","article-title":"The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease","volume":"8","author":"Price","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.120.000133_bib251","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12035-013-8622-4","article-title":"Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells","volume":"50","author":"Pyszko","year":"2014","journal-title":"Mol Neurobiol"},{"key":"10.1124\/pharmrev.120.000133_bib252","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018568","article-title":"Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2","volume":"6","author":"Ramonet","year":"2011","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.120.000133_bib253","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ana.24066","article-title":"Lewy body extracts from Parkinson disease brains trigger \u03b1-synuclein pathology and neurodegeneration in mice and monkeys","volume":"75","author":"Recasens","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib254","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s11064-016-2125-4","article-title":"FTY720 attenuates 6-OHDA-associated dopaminergic degeneration in cellular and mouse Parkinsonian models","volume":"42","author":"Ren","year":"2017","journal-title":"Neurochem Res"},{"key":"10.1124\/pharmrev.120.000133_bib255","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13311-014-0294-x","article-title":"A GCase chaperone improves motor function in a mouse model of synucleinopathy","volume":"11","author":"Richter","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1124\/pharmrev.120.000133_bib256","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00702-019-02025-9","article-title":"\u03b1-Synuclein in Parkinson\u2019s disease: causal or bystander?","volume":"126","author":"Riederer","year":"2019","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1124\/pharmrev.120.000133_bib257","series-title":"Protein Folding and Misfolding: Neurodegenerative Diseases","first-page":"175","article-title":"Inhibition of \u03b1-synuclein aggregation by antioxidants and chaperones in Parkinson\u2019s disease","author":"Rochet","year":"2009"},{"key":"10.1124\/pharmrev.120.000133_bib258","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/B978-0-12-385883-2.00011-4","article-title":"Molecular insights into Parkinson\u2019s disease","volume":"107","author":"Rochet","year":"2012","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1124\/pharmrev.120.000133_bib259","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00702-010-0513-5","article-title":"The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen","volume":"118","author":"Rogers","year":"2011","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1124\/pharmrev.120.000133_bib260","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/15548627.2018.1535292","article-title":"Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration","volume":"15","author":"Rusmini","year":"2019","journal-title":"Autophagy"},{"key":"10.1124\/pharmrev.120.000133_bib261","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/WCO.0000000000000715","article-title":"GBA1-associated parkinsonism: new insights and therapeutic opportunities","volume":"32","author":"Ryan","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib262","doi-asserted-by":"crossref","first-page":"31380","DOI":"10.1038\/srep31380","article-title":"Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models","volume":"6","author":"Sanchez-Martinez","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.120.000133_bib263","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7554\/eLife.46775","article-title":"Inhibition of synucleinopathic seeding by rationally designed inhibitors","volume":"9","author":"Sangwan","year":"2020","journal-title":"eLife"},{"key":"10.1124\/pharmrev.120.000133_bib264","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.expneurol.2005.12.024","article-title":"Silencing of human \u03b1-synuclein in vitro and in rat brain using lentiviral-mediated RNAi","volume":"198","author":"Sapru","year":"2006","journal-title":"Exp Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib265","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.27414","article-title":"Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic","volume":"33","author":"Sardi","year":"2018","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib266","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1073\/pnas.1220464110","article-title":"Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies","volume":"110","author":"Sardi","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib267","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.1616152114","article-title":"Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models","volume":"114","author":"Sardi","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib268","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neuro.2014.07.006","article-title":"Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson\u2019s disease mouse model","volume":"44","author":"Sarkar","year":"2014","journal-title":"Neurotoxicology"},{"key":"10.1124\/pharmrev.120.000133_bib269","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1001\/archneurol.2010.135","article-title":"When does Parkinson disease start?","volume":"67","author":"Savica","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib270","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.nbd.2017.12.005","article-title":"Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble \u03b1-synuclein in neurons","volume":"111","author":"Schapansky","year":"2018","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000133_bib271","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-\u03b1-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib272","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","article-title":"Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies","volume":"12","author":"Schmid","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"10.1124\/pharmrev.120.000133_bib273","doi-asserted-by":"crossref","first-page":"104582","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000133_bib274","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1038\/ncomms5028","article-title":"iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis","volume":"5","author":"Sch\u00f6ndorf","year":"2014","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000133_bib275","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/mds.27782","article-title":"Antisense therapies for movement disorders","volume":"34","author":"Scoles","year":"2019","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib276","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","article-title":"Discovery of a 3-(4-pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity","volume":"60","author":"Scott","year":"2017","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.120.000133_bib277","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ana.25341","article-title":"\u03b22-adrenoreceptor medications and risk of Parkinson disease","volume":"84","author":"Searles Nielsen","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib278","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2174\/1567205011666140616113406","article-title":"An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer\u2019s disease","volume":"11","author":"Shah","year":"2014","journal-title":"Curr Alzheimer Res"},{"key":"10.1124\/pharmrev.120.000133_bib279","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000133_bib280","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson\u2019s disease","volume":"41","author":"Sim\u00f3n-S\u00e1nchez","year":"2009","journal-title":"Nat Genet"},{"key":"10.1124\/pharmrev.120.000133_bib281","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of nilotinib in patients with moderately advanced Parkinson disease","volume":"78","author":"Simuni","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib282","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson\u2019s disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000133_bib283","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.parkreldis.2009.09.008","article-title":"alpha-Synuclein multiplication analysis in Italian familial Parkinson disease","volume":"16","author":"Sironi","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1124\/pharmrev.120.000133_bib284","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1523\/JNEUROSCI.0482-05.2005","article-title":"Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells","volume":"25","author":"Smith","year":"2005","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib285","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.neuron.2016.09.037","article-title":"A LRRK2-dependent endophilinA phosphoswitch is critical for macroautophagy at presynaptic terminals","volume":"92","author":"Soukup","year":"2016","journal-title":"Neuron"},{"key":"10.1124\/pharmrev.120.000133_bib286","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1523\/JNEUROSCI.4390-09.2009","article-title":"Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson\u2019s and Lewy body diseases","volume":"29","author":"Spencer","year":"2009","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib287","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-016-0410-8","article-title":"Anti-\u03b1-synuclein immunotherapy reduces \u03b1-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy","volume":"5","author":"Spencer","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1124\/pharmrev.120.000133_bib288","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acn3.321","article-title":"\u03b1-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease","volume":"3","author":"Spencer","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib289","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000133_bib290","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbadis.2007.12.006","article-title":"Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson\u2019s disease","volume":"1782","author":"Stack","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/pharmrev.120.000133_bib291","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41421-020-0158-y","article-title":"Mendelian neurodegenerative disease genes involved in autophagy","volume":"6","author":"Stamatakou","year":"2020","journal-title":"Cell Discov"},{"key":"10.1124\/pharmrev.120.000133_bib292","doi-asserted-by":"crossref","first-page":"S4.001","DOI":"10.1212\/WNL.92.15_supplement.S4.001","article-title":"A first in human study of PBT434, a novel small molecule inhibitor of \u03b1-synuclein aggregation (S4.001)","volume":"92","author":"Stamler","year":"2019","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000133_bib293","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1212\/WNL.94.15_supplement.4871","article-title":"A phase 1 study of PBT434, a novel small molecule inhibitor of \u03b1-synuclein aggregation, in adult and older adult volunteers (4871)","volume":"94","author":"Stamler","year":"2020","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000133_bib294","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib295","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainres.2010.03.079","article-title":"Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice","volume":"1335","author":"Sun","year":"2010","journal-title":"Brain Res"},{"key":"10.1124\/pharmrev.120.000133_bib296","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","article-title":"Glucosylsphingosine promotes \u03b1-synuclein pathology in mutant GBA-associated Parkinson\u2019s disease","volume":"37","author":"Taguchi","year":"2017","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib297","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.14","article-title":"Normalization of overexpressed \u03b1-synuclein causing Parkinson\u2019s disease by a moderate gene silencing with RNA interference","volume":"4","author":"Takahashi","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/pharmrev.120.000133_bib298","first-page":"100750","article-title":"Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin","volume":"22","author":"Tanaka","year":"2020","journal-title":"Biochem Biophys Rep"},{"key":"10.1124\/pharmrev.120.000133_bib299","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1074\/jbc.M310994200","article-title":"Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective","volume":"279","author":"Tanaka","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib300","doi-asserted-by":"crossref","first-page":"15194","DOI":"10.1074\/jbc.M113.457408","article-title":"Lewy body-like \u03b1-synuclein aggregates resist degradation and impair macroautophagy","volume":"288","author":"Tanik","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib301","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00401-015-1526-9","article-title":"Pathological \u03b1-synuclein distribution in subjects with coincident Alzheimer\u2019s and Lewy body pathology","volume":"131","author":"Toledo","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000133_bib302","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","article-title":"\u0391-synuclein immunotherapy blocks uptake and templated propagation of misfolded \u03b1-synuclein and neurodegeneration","volume":"7","author":"Tran","year":"2014","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.120.000133_bib303","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.neurobiolaging.2005.04.004","article-title":"Neuroprotective effects of cystamine in aged parkinsonian mice","volume":"27","author":"Tremblay","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.1124\/pharmrev.120.000133_bib304","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/mds.27527","article-title":"Genotype-phenotype relations for the Parkinson\u2019s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review","volume":"33","author":"Trinh","year":"2018","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib305","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","article-title":"\u03b1-synuclein in the pathophysiology of Alzheimer\u2019s disease","volume":"14","author":"Twohig","year":"2019","journal-title":"Mol Neurodegener"},{"key":"10.1124\/pharmrev.120.000133_bib306","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1212\/01.wnl.0000327607.28928.e6","article-title":"Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication","volume":"71","author":"Uchiyama","year":"2008","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.120.000133_bib307","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/mds.28558","article-title":"Perampanel inhibits \u03b1-synuclein transmission in Parkinson\u2019s disease models","volume":"36","author":"Ueda","year":"2021","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib308","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","article-title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease","volume":"90","author":"U\u00e9da","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib309","doi-asserted-by":"crossref","first-page":"7567","DOI":"10.1038\/s41598-019-43772-9","article-title":"Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting \u03b1-synuclein as a novel therapy for Parkinson\u2019s disease","volume":"9","author":"Uehara","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.120.000133_bib310","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.molmed.2020.03.012","article-title":"Cell-to-cell transmission of Tau and \u03b1-synuclein","volume":"26","author":"Uemura","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1124\/pharmrev.120.000133_bib311","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/emmm.201302475","article-title":"Caudo-rostral brain spreading of \u03b1-synuclein through vagal connections","volume":"5","author":"Ulusoy","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1124\/pharmrev.120.000133_bib312","doi-asserted-by":"crossref","first-page":"44284","DOI":"10.1074\/jbc.M105343200","article-title":"Metal-triggered structural transformations, aggregation, and fibrillation of human \u03b1-synuclein. A possible molecular NK between Parkinson\u2019s disease and heavy metal exposure","volume":"276","author":"Uversky","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib313","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","article-title":"Immunotherapeutic approaches targeting amyloid-\u03b2, \u03b1-synuclein, and Tau for the treatment of neurodegenerative disorders","volume":"13","author":"Valera","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1124\/pharmrev.120.000133_bib314","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2019.05.029","article-title":"FTY720 improves behavior, increases brain derived neurotrophic factor levels and reduces \u03b1-synuclein pathology in Parkinsonian GM2+\/- mice","volume":"411","author":"Vidal-Martinez","year":"2019","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.120.000133_bib315","doi-asserted-by":"crossref","first-page":"20811","DOI":"10.1074\/jbc.M116.744029","article-title":"FTY720\/Fingolimod reduces synucleinopathy and improves gut motility in A53T mice: contributions of pro-brain-derived neurotrophic factor (pro-BDNF) and mature BDNF","volume":"291","author":"Vidal-Mart\u00ednez","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib316","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.celrep.2018.11.028","article-title":"Inhibiting stearoyl-CoA desaturase ameliorates \u03b1-synuclein cytotoxicity","volume":"25","author":"Vincent","year":"2018","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.120.000133_bib317","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/med.21402","article-title":"Therapeutic strategies and pharmacological tools influencing S1P signaling and metabolism","volume":"37","author":"Vogt","year":"2017","journal-title":"Med Res Rev"},{"key":"10.1124\/pharmrev.120.000133_bib318","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib319","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000133_bib320","doi-asserted-by":"crossref","first-page":"108843","DOI":"10.1016\/j.biopha.2019.108843","article-title":"Progress of immunotherapy of anti-\u03b1-synuclein in Parkinson\u2019s disease","volume":"115","author":"Wang","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1124\/pharmrev.120.000133_bib321","doi-asserted-by":"crossref","first-page":"25009","DOI":"10.1074\/jbc.M300227200","article-title":"Alpha-Synuclein is degraded by both autophagy and the proteasome","volume":"278","author":"Webb","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000133_bib322","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00401-019-02023-x","article-title":"Depopulation of dense \u03b1-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson\u2019s disease model","volume":"138","author":"Wegrzynowicz","year":"2019","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.120.000133_bib323","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1124\/pharmrev.120.000133_bib324","doi-asserted-by":"crossref","first-page":"13709","DOI":"10.1021\/bi961799n","article-title":"NACP, a protein implicated in Alzheimer\u2019s disease and learning, is natively unfolded","volume":"35","author":"Weinreb","year":"1996","journal-title":"Biochemistry"},{"key":"10.1124\/pharmrev.120.000133_bib325","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3233\/JPD-202076","article-title":"Squalamine restores the function of the enteric nervous system in mouse models of Parkinson\u2019s disease","volume":"10","author":"West","year":"2020","journal-title":"J Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib326","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/JPD-191576","article-title":"Extended treatment with glial cell line-derived neurotrophic factor in Parkinson\u2019s disease","volume":"9","author":"Whone","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib327","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1750-3639.2010.00429.x","article-title":"Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson\u2019s disease brain","volume":"21","author":"Wilhelmus","year":"2011","journal-title":"Brain Pathol"},{"key":"10.1124\/pharmrev.120.000133_bib328","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib329","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1083\/jcb.201003122","article-title":"\u03b1-Synuclein impairs macroautophagy: implications for Parkinson\u2019s disease","volume":"190","author":"Winslow","year":"2010","journal-title":"J Cell Biol"},{"key":"10.1124\/pharmrev.120.000133_bib330","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/brain\/aww238","article-title":"A de novo compound targeting \u03b1-synuclein improves deficits in models of Parkinson\u2019s disease","volume":"139","author":"Wrasidlo","year":"2016","journal-title":"Brain"},{"key":"10.1124\/pharmrev.120.000133_bib331","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.neuroscience.2014.11.004","article-title":"Rotenone impairs autophagic flux and lysosomal functions in Parkinson\u2019s disease","volume":"284","author":"Wu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.120.000133_bib332","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3233\/JPD-160904","article-title":"Nilotinib - differentiating the hope from the hype","volume":"6","author":"Wyse","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"10.1124\/pharmrev.120.000133_bib333","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/mds.101","article-title":"Noninvasive delivery of an \u03b1-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound","volume":"33","author":"Xhima","year":"2018","journal-title":"Mov Disord"},{"key":"10.1124\/pharmrev.120.000133_bib334","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fnagi.2017.00308","article-title":"DJ-1 inhibits \u03b1-synuclein aggregation by regulating chaperone-mediated autophagy","volume":"9","author":"Xu","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1124\/pharmrev.120.000133_bib335","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13024-018-0241-0","article-title":"Extracellular \u03b1-synuclein levels are regulated by neuronal activity","volume":"13","author":"Yamada","year":"2018","journal-title":"Mol Neurodegener"},{"key":"10.1124\/pharmrev.120.000133_bib336","doi-asserted-by":"crossref","first-page":"E12053","DOI":"10.1073\/pnas.1813365115","article-title":"Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson\u2019s disease and DLB","volume":"115","author":"Yan","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib337","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000133_bib338","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.120.000133_bib339","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuroscience.2020.05.047","article-title":"Transglutaminase 2 depletion attenuates \u03b1-synuclein mediated toxicity in mice","volume":"441","author":"Zhang","year":"2020","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.120.000133_bib340","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1073\/pnas.1905057117","article-title":"Translation of the intrinsically disordered protein \u03b1-synuclein is inhibited by a small molecule targeting its structured mRNA","volume":"117","author":"Zhang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000133_bib341","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13578-019-0282-2","article-title":"Exosomes: biogenesis, biologic function and clinical potential","volume":"9","author":"Zhang","year":"2019","journal-title":"Cell Biosci"},{"key":"10.1124\/pharmrev.120.000133_bib342","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 antisense oligonucleotides ameliorate \u03b1-synuclein inclusion formation in a Parkinson\u2019s disease mouse model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/pharmrev.120.000133_bib343","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting \u03b1-synuclein prevents neurodegeneration in a Parkinson\u2019s disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000133_bib344","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","article-title":"Reversible conformational conversion of \u03b1-synuclein into toxic assemblies by glucosylceramide","volume":"97","author":"Zunke","year":"2018","journal-title":"Neuron"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724007026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724007026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.120.000133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:37:20Z","timestamp":1740746240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724007026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":344,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0031699724007026"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.120.000133","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutics in the Pipeline Targeting \u03b1-Synuclein for Parkinson's Disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.120.000133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The Author(s)","name":"copyright","label":"Copyright"}]}}